Characterization of the genetic variation present in CYP3A4 in three South African populations

Frontiers in Genetics

Volumn 4, Issue FEB, 2013, Pages

  Drögemöller, Britt ^a   Plummer, Marieth ^a   Korkie, Lundi ^a   Agenbag, Gloudi ^a   Dunaiski, Anke ^a   Niehaus, Dana ^a   Koen, Liezl ^a   Gebhardt, Stefan ^a   Schneider, Nicol ^a   Olckers, Antonel ^b   Wright, Galen ^a   Warnich, Louise ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF PRETORIA   (South Africa)

Author keywords

CYP3A4; Khoisan; Mixed ancestry; Pharmacogenetics; South African populations; Xhosa

Indexed keywords

EID: 84876173508     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2013.00017     Document Type: Article

References (38)

1. Amirimani, B., Ning, B., Deitz, A. C., Weber, B. L., Kadlubar, E E, and Rebbeck, T. R. (2003). Increased transcriptional activity of the CYP3A4*1B variant. Environ. Mol. Mutagen. 42, 299-305.
2. Angiolillo, D. J., Fernandez-Ortiz, A., Bernardo, E., Ramírez, C., Cavallari, U., Trabetti, E., et al. (2006). Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel. Arterioscler. Thromb. Vasc. Biol. 26, 1895-1900.
3. Chen, C. H., Wang, S. C., Tsou, H. H., Ho, I. K., Tian, J. N., Yu, C. J., et al. (2011). Genetic polymorphisms in CYP3A4 are associated with withdrawal symptoms and adverse reactions in methadone maintenance patients. Pharmacogenomics 12, 1397-1406.
4. Chen, Y. S., Olckers, A., Schurr, T., Kogelnik, A., Huoponen, K., and Wallace, D. (2000). mtDNA Variation in the South African Kung and Khwe-and their genetic relationships to other African populations. Am. J. Hum. Genet. 66, 1362-1383.
5. De Wit, E., Delport, W., Rugamika, C. E., Meintjes, A., Möller, M., van Helden, P. D., et al. (2010). Genome-wide analysis of the structure of the South African Coloured Population in the Western Cape. Hum. Genet. 128, 145-153.
6. Drögemöller, B. I., Wright, G. E., Niehaus, D. J., Emsley, R. A., and Warnich, L. (2011). Whole-genome resequencing in pharmacogenomics: moving away from past disparities to globally representative applications. Pharmacogenomics 12, 1717-1728.
7. Drögemöller, B. I., Wright, G. E., Niehaus, D. J., Koen, L., Malan, S., Da Silva, D. M., et al. (2010). Characterization of the genetic profile of CYP2C19 in two South African populations. Pharmacogenomics 11, 1095-1103.
8. Eiselt, R., Domanski, T. L., Zibat, A., Mueller, R., Presecan-Siedel, E., Hustert, E., et al. (2001). Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11,447-458.
9. Elens, L., Bouamar, R., Hesselink, D. A., Haufroid, V., van Gelder, T., and van Schaik, R. H. (2012). The new CYP3A4 intron 6 C>T polymorphism (CYP3A4Elens, L., Bouamar22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenet. Genomics 22, 373-380.
10. Elens, L., van Schaik, R. H., Panin, N., de Meyer, M., Wallemacq, P., Lison, D., et al. (2011). Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics 12, 1383-1396.
11. Kundaje, A., Aldred, S. E, Collins, P. J., Davis, C. A., et al. (2012). An integrated encyclopedia of DNA elements in the human genome. ENCODE Project Consortium, Nature 489, 57-74.
12. Galanter, J. M., Fernandez-Lopez, J. C., Gignoux, C. R., Barnholtz-Sloan, J., Fernandez-Rozadilla, C., Via, M., et al. (2012). Development of a panel of genome-wide ancestry informative markers to study admixture throughout the Americas. PLoS Genet. 8:e1002554. doi: 10.1371/journal.pgen.1002554
13. Georgitsi, M., Zukic, B., Pavlovic, S., and Patrinos, G. P. (2011). Transcriptional regulation and pharmacogenomics. Pharmacogenomics 12, 655-673.
14. Guengerich, F. P. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol. 39, 1-17.
15. Ikediobi, O., Aouizerat, B., Xiao, Y., Gandhi, M., Gebhardt, S., and Warnich, L. (2011). Analysis of pharmacogenetic traits in two distinct South African populations. Hum. Genomics 5, 265-282.
16. Kaessmann, H., and Pääbo, S. (2002). The genetical history of humans and the great apes. J. Intern. Med. 251, 1-18.
17. Lamba, J. K., Lin, Y S., Schuetz, E. G., and Thummel, K. E. (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug Deliv. Rev. 54, 1271-1294.
18. Lown, K. S., Thummel, K. E., Benedict, P. E., Shen, D. D., Turgeon, D. K., Berent, S., et al. (1995). The erythromycin breath test predicts the clearance of mida-zolam. Clin. Pharmacol. Ther. 57, 16-24.
19. Ng, P. C., and Henikoff, S. (2003). SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res. 31,3812-3814
20. Quintana-Murci, L., Harmant, C., Quach, H., Balanovsky, O., Zaporozhchenko, V., Bormans, C., et al. (2010). Strong maternal Khoisan contribution to the South African coloured population: a case of gender-biased admixture. Am. J. Hum. Genet. 86, 611-620.
21. Ramensky, V., Bork, P., and Sunyaev, S. (2002). Human non-synonymous SNPs: server and survey. Nucleic Acids Res. 30,3894-3900.
22. Rosenberg, N. A., Huang, L., Jewett, E. M., Szpiech, Z. A., Jankovic, I., and Boehnke, M. (2010). Genome-wide association studies in diverse populations. Nat. Rev. Genet. 11, 356-366.
23. Schlebusch, C. M., Naidoo, T., and Soodyall, H. (2009). SNaPshot minisequencing to resolve mito-chondrial macro-haplogroups found in Africa. Electrophoresis 30, 3657-3664.
24. Schuster, S. C., Miller, W., Ratan, A., Tomsho, L. P., Giardine, B., Kasson, L. R., et al. (2010). Complete Khoisan and Bantu genomes from southern Africa. Nature 463, 943-947.
25. Sevrioukova, I. F., and Poulos, T. L. (2013). Understanding the mechanism of cytochrome P450 3A4: recent advances and remaining problems. Dalton Trans. 42, 3116-3126.
26. Shimada, T., and Guengerich, F. P. (1989). Evidence for cytochrome P-450NF, the nifedipine oxidase, being the principal enzyme involved in the bioactivation of aflatoxins in human liver. Proc. Natl. Acad. Sci. U.S.A. 86, 462-465.
27. Steimer, E. M., and Potter, J. M. (2002). Pharmacogenetic screening and therapeutic drugs. Clin. Chim. Acta315, 137-155.
28. Suarez-Kurtz,G. (2005) Pharmacogenomics in admixed populations. Trends Pharmacol. Sci. 26, 196-201
29. Suarez-Kurtz,G (2010). Pharmacogenetics in the Brazilian population. Front. Pharmacol 1:118. doi: 10.3389/fphar.2010. 00118
30. Suarez-Kurtz, G., Pena, S. D., Struchiner, C. J., and Hutz, M. H. (2012). Pharmacogenomic diversity among Brazilians: influence of ancestry, self-reported color, and geographical origin. Front. Pharmacol. 3:191. doi: 10.3389/ fphar.2012.00191
31. The 1000 Genomes Project Consortium. (2010). A map of human genome variation from population-scale sequencing. Nature 467, 1061-1073.
32. Tishkoff, S. A., Reed, E A., Friedlaender, F R., Ehret, C., Ranciaro, A., Froment, A., et al. (2009). The genetic structure and history of Africans and African Americans. Science 324, 1035-1044.
33. Wang, D., Guo, Y., Wrighton, S. A., Cooke, G. E., and Sadee, W. (2011). Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs. Pharmacogenomics J. 11,274-286.
34. Warnich, L., Drögemöller, B. I., Pepper, M. S., Dandara, C., and Wright, G E. (2011). Pharmacogenomic research in South Africa: lessons learned and future opportunities in the rainbow nation. Curr. Pharmacogenomics Person. Med. 9, 191-207.
35. Westlind, A., Lofberg, L., Tindberg, N., Andersson, T. B., and Ingelman-Sundberg, M. (1999). Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5;-upstream regulatory region. Biochem. Biophys. Res. Commun. 259, 201-205.
36. Westlind-Johnsson, A., Hermann, R., Huennemeyer, A., Hauns, B., Lahu, G., Nassr, N., et al. (2006). Identification and characterization of CYP3A4Westlind-Johnsson, A., Hermann, R.20, a novel rare CYP3A4 allele without functional activity. Clin. Pharmacol Ther. 79, 339-349.
37. Whirl-Carrillo, M., McDonagh, E. M., Hebert, J. M., Gong, L., Sangkuhl, K., Thorn, C. F., et al. (2012). Pharmacogenomics knowledge for personalized medicine. Clin. Pharmacol. Ther. 92, 414-417.
38. Wright, G. E., Niehaus, D. J., Drögemöller, B. I., Koen, L., Gaedigk, A., and Warnich, L. (2010). Elucidation of CYP2D6 genetic diversity in a unique African population:implications for the future application of pharmacogenetics in the Xhosa population. Ann. Hum. Genet. 74, 340-350